Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer
Overview
Authors
Affiliations
Bexarotene is a rexinoid that has been shown to prevent mammary tumors in mouse models but oral dosing has toxicities. This phase I study evaluates topical bexarotene, as a potential chemoprevention agent, for safety and toxicity in high-risk women for breast cancer.
Shahab M, Al-Madhagi H, Zheng G, Zeb A, Alasmari A, Alharbi M Sci Rep. 2023; 13(1):14466.
PMID: 37660065 PMC: 10475047. DOI: 10.1038/s41598-023-41325-9.
Zheng C, Guo H, Mo Y, Liu G Recent Pat Anticancer Drug Discov. 2023; 19(5):681-694.
PMID: 37653627 DOI: 10.2174/1574892819666230831112815.
Targeting nuclear hormone receptors for the prevention of breast cancer.
Moyer C, Brown P Front Med (Lausanne). 2023; 10:1200947.
PMID: 37583424 PMC: 10424511. DOI: 10.3389/fmed.2023.1200947.